

# Hiltrun Haibel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4875576/publications.pdf>

Version: 2024-02-01

60  
papers

5,077  
citations

136940

32  
h-index

168376

53  
g-index

63  
all docs

63  
docs citations

63  
times ranked

2710  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comment on "Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis" by Kuwabara <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e93-e93.	0.9	7
2	B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. <i>Arthritis and Rheumatology</i> , 2022, 74, 934-947.	5.6	55
3	Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210859.	2.7	6
4	Presence of spondyloarthritis associated to higher disease activity and HLA-B27 positivity in patients with early Crohn's disease: Clinical and MRI results from a prospective inception cohort. <i>Joint Bone Spine</i> , 2022, 89, 105367.	1.6	9
5	Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results. <i>Rheumatology</i> , 2022, 61, 3299-3308.	1.9	16
6	Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2022, 74, 1515-1523.	5.6	11
7	Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1252-1259.	0.9	7
8	Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance. <i>Arthritis Research and Therapy</i> , 2021, 23, 106.	3.5	37
9	Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis. <i>RMD Open</i> , 2021, 7, e001751.	3.8	3
10	Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2098770.	2.7	6
11	The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. <i>Arthritis Research and Therapy</i> , 2020, 22, 210.	3.5	16
12	Relation of $\beta$ -2-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9383.	4.1	1
13	The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097261.	2.7	17
14	Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 3798-3806.	1.9	52
15	Response to "Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier" by Alunno <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e55-e55.	0.9	0
16	Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 126.	3.5	2
17	Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. <i>Rheumatology</i> , 2019, 58, 1634-1638.	1.9	100
18	SAT0347...COMORBID CONDITIONS ARE ASSOCIATED WITH HIGHER DISEASE ACTIVITY AND WORSE FUNCTIONAL STATUS IN AXIAL SPONDYLOARTHRITIS: A POPULATION-BASED ANALYSIS OF INSURANCE CLAIMS LINKED TO PATIENT SURVEY DATA. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	THU0365â€¦THE IMPACT OF UVEITIS, PSORIASIS AND INFLAMMATORY BOWEL DISEASE ON MUSCULOSKELETAL DISEASE ACTIVITY AND FUNCTION IN AXIAL SPONDYLOARTHRITIS: A POPULATION-BASED ANALYSIS OF INSURANCE CLAIMS LINKED TO PATIENT SURVEY DATA. , 2019, , .		1
20	SAT0305â€¦ASSOCIATION OF SKIN PSORIASIS WITH CLINICAL AND RADIOGRAPHIC CHARACTERISTICS IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT. , 2019, , .		0
21	Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Longâ€¦Term Antiâ€¦Tumor Necrosis Factor Treatment: Sixâ€¦Year Results of Continuous Treatment With Etanercept. Arthritis and Rheumatology, 2019, 71, 722-728.	5.6	21
22	Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort. Rheumatology, 2018, 57, 703-711.	1.9	37
23	Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Annals of the Rheumatic Diseases, 2018, 77, 1017-1024.	0.9	44
24	Chronic meningococcaemiaâ€¦a medical oxymoron. Rheumatology, 2017, 56, 1819-1821.	1.9	0
25	Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Research and Therapy, 2017, 19, 240.	3.5	43
26	High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort. Annals of the Rheumatic Diseases, 2016, 75, 2114-2118.	0.9	103
27	Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-â€¦Inhibitors for Up to 10 Years. Journal of Rheumatology, 2016, 43, 2142-2148.	2.0	38
28	Comparison of Clinical Examination versus Whole-body Magnetic Resonance Imaging of Enthesitis in Patients with Early Axial Spondyloarthritis during 3 Years of Continuous Etanercept Treatment. Journal of Rheumatology, 2016, 43, 618-624.	2.0	22
29	Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritisâ€¦3-Year data of the ESTHER trial. Seminars in Arthritis and Rheumatism, 2016, 45, 404-410.	3.4	33
30	Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort. Arthritis and Rheumatology, 2015, 67, 2369-2375.	5.6	28
31	Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. Rheumatology, 2015, 54, 257-261.	1.9	18
32	Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression. Arthritis and Rheumatology, 2015, 67, 678-685.	5.6	67
33	Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 1746-1748.	0.9	71
34	Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. Arthritis Research and Therapy, 2014, 16, R35.	3.5	32
35	Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 2137-2143.	0.9	62
36	Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8â€¦years in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 710-715.	0.9	238

#	ARTICLE	IF	CITATIONS
37	Consistently Good Clinical Response in Patients with Early Axial Spondyloarthritis After 3 Years of Continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial. <i>Journal of Rheumatology</i> , 2014, 41, 2034-2040.	2.0	27
38	Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort (GESPIC). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1430-1432.	0.9	67
39	Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. <i>Arthritis Research and Therapy</i> , 2013, 15, R67.	3.5	44
40	Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 823-825.	0.9	100
41	Magnetic Resonance Imaging Compared to Conventional Radiographs for Detection of Chronic Structural Changes in Sacroiliac Joints in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1557-1565.	2.0	55
42	Vertebral Erosions Associated with Spinal Inflammation in Patients with Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes After 2 Years of Tumor Necrosis Factor Inhibitor Therapy. <i>Journal of Rheumatology</i> , 2013, 40, 1891-1896.	2.0	17
43	Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 967-973.	0.9	109
44	A4.11 Baseline Elevated Serum Levels of Calprotectin as Independent Marker for Radiographic Spinal Progression in Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A28.1-A28.	0.9	0
45	Evaluation of the spinal pain score in AS—a psychometric analysis. <i>Rheumatology</i> , 2012, 51, 2155-2163.	1.9	2
46	Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1212-1215.	0.9	82
47	High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 572-574.	0.9	201
48	Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1616-1622.	0.9	286
49	Baseline radiographic damage, elevated acute phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1388-1398.	6.7	384
50	Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. <i>Rheumatology</i> , 2011, 50, 1690-1699.	1.9	105
51	Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1369-1374.	0.9	293
52	Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?. <i>Current Opinion in Rheumatology</i> , 2010, 22, 388-392.	4.3	14
53	The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort. <i>Arthritis and Rheumatism</i> , 2009, 60, 717-727.	6.7	605
54	Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 3257-3262.	6.7	282

#	ARTICLE	IF	CITATIONS
55	Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. <i>Arthritis and Rheumatism</i> , 2008, 58, 1981-1991.	6.7	293
56	Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 678-681.	6.7	150
57	Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. <i>Journal of Rheumatology</i> , 2004, 31, 531-8.	2.0	65
58	Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. <i>Journal of Rheumatology</i> , 2002, 29, 118-22.	2.0	103
59	Infliximab treatment of severe ankylosing spondylitis: One-year followup. <i>Arthritis and Rheumatism</i> , 2001, 44, 2936-2937.	6.7	76
60	Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor $\alpha$ monoclonal antibody infliximab. <i>Arthritis and Rheumatism</i> , 2000, 43, 1346-1352.	6.7	506